Primary care practitioners: An analysis of their perceptions of voiding dysfunction and prostate cancer

Journal of Urology

Volumn 155, Issue 2, 1996, Pages 601-604

  Plawker, Marc W ^a   Fleisher, Jay M ^a   Nitti, Victor W ^a   Macchia, Richard J ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

primary health care; prostate; prostatic neoplasms; urination disorders

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; TERAZOSIN;

ADULT; ARTICLE; CLINICAL PRACTICE; FINGER; HUMAN; MICTURITION DISORDER; MULTIPLE CHOICE TEST; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RECTUM;

EID: 0030028902     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66462-0     Document Type: Article

References (10)

1. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. A.: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age specific reference ranges. J.A.M.A., 270: 860, 1993.
2. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909, 1987.
3. Chybowski, F. M., Bergstralh, E. J. and Oesterling, J. E.: The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J. Urol., 148: 83, 1992.
4. Guess, H. A., Heyse, J. F., Gormley, G. J., Stoner, E. and Oesterling, J. E.: Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol. Clin. N. Amer., 20: 627, 1993.
5. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, R. C., Walsh, J., McConnell, J. D., Andriole, G. I., Geller, J., Bracken, B. R. and Tenover, J. S.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. J. Med., 327: 1185, 1992.
6. Guess, H. A., Heyse, J. F. and Gormley, G. J.: The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate, 22: 31, 1993.
7. U. S. Department of Health and Human Services: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline 8. Rockville, Maryland: AHCPR Publications, No. 94-0582, 1994.
8. Arrighi, H. M., Guess, H. A., Metter, E. J. and Fozard, J. L.: Symptoms and signs of prostatism as high risk factors for prostatectomy. Prostate, 16: 253, 1990.
9. Mukamel, E., Nissenkorn, I., Boner, G. and Servadio, C.: Occult progressive renal damage in the elderly male due to benign prostatic hypertrophy. J. Amer. Geriatr. Soc., 27: 403, 1979.
10. Calman, N. S., Hyman, R. B. and Licht, W.: Variability in consultation rates and practitioner level of diagnostic certainty. J. Fam. Prac., 35: 31, 1992.